Highlights from WIN 2019

Goals of the WIN Consortium

Rapidly changing landscape of precision medicine in Japan

Use of platform studies for the evaluation of innovative combinations in solid tumours and haematologic malignancies

Optimising patient enrolment and efficacy of precision oncology clinical trials

How will ASCO combat cancer disparities?

CD-19 mutation frequency after blinatumomab treatment is lower than after CAR T-cell therapy

HORIZON update: Using melflufen to treat RRMM patients refractory to daratumumab and/or pomalidomide

The changing landscape of AML

Using bioinformatics and genomics to treat AML

MOR208 plus lenalidomide in r-r diffuse large B-cell lymphoma

Chemoimmunotherapy or BTK inhibition for patients with CLL